Inferra AI / Company / PCRX
Pacira BioSciences, Inc.
PCRX · Health Care
Last earnings Oct 8, 2026
Key results
Total revenuequarter
$181.1 million
Total revenues of $181.1 million Net product sales of $142.9 million for EXPAREL, $31.3 million for ZILRETTA, and $5.6 million for iovera Net loss of $4.8 million, or $0.11 per share (basic and diluted) Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $54.3 million
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Revenuequarter
$142.9 million
Total revenues of $181.1 million Net product sales of $142.9 million for EXPAREL, $31.3 million for ZILRETTA, and $5.6 million for iovera Net loss of $4.8 million, or $0.11 per share (basic and diluted) Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $54.3 million
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Adjusted EPSquarter
$0.11
Total revenues of $181.1 million Net product sales of $142.9 million for EXPAREL, $31.3 million for ZILRETTA, and $5.6 million for iovera Net loss of $4.8 million, or $0.11 per share (basic and diluted) Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $54.3 million
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Second Quarter 2025 Financial Results Total revenues were $181.1 million in the second quarter of 2025, versus $178.0 million reported for the second quarter of 2024.
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Non-GAAP net incomequarter
$36.0 million
Non-GAAP net income was $36.0 million, or $0.79 per share (basic) and $0.74 per share (diluted) in the second quarter of 2025, compared to $44.2 million, or $0.96 per share (basic) and $0.89 per share (diluted), in the second quarter of 2024.
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
AI analysis
Q2 2025 · reported Aug 5, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · Aug 5, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Total revenue | $181.1 million | — | — |
| Revenue | $142.9 million | — | — |
| Adjusted EPS | $0.11 | — | — |
| Non-GAAP net income | $36.0 million | — | — |
Guidance · company-stated
Direction: Raised
“2025 Financial Guidance Today the company is updating its full-year 2025 total revenue and non-GAAP gross margin guidance as follows Total revenue is narrowed to the range of $730 million to $750 million versus the previously guided range of $725 million to $765 million and Non-GAAP gross margin is increased to 78 to 80 percent versus the previously guided range of 76 to 78 percent.”
“Pacira is reiterating its remaining full-year 2025 financial guidance as follows Non-GAAP R D expense of $90 million to $105 million Non-GAAP SG A expense of $290 million to $320 million and Stock-based compensation of $56 million to $61 million.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Second Quarter 2025 Financial Highlights Total revenues of $181.1 million Net product sales of $142.9 million for EXPAREL, $31.3 million for ZILRETTA, and $5.6 million for iovera Net loss of $4.8 million, or $0.11 per share (basic and diluted) Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $54.3 million Non-GAAP net income of $36.0 million, or $0.79 per share (basic) and $0.74 per share (diluted) Repurchased 2.0 million shares of common stock at an average price of $25.59 per share, for a cost of $50.0 million See Non-GAAP Financial Information below.
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue +303.1% computed from stated figures
Event summary
The company remains on track to complete enrollment in Part A of the study before the end of 2025 and report results from an interim analysis before the end of 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “2025 Financial Guidance Today the company is updating its full-year 2025 total revenue and non-GAAP gross margin guidance as follows Total revenue is narrowed to the range of $730 million to $750 million versus the previously guided range of $725 million to $765 million and Non-GAAP gross margin is increased to 78 to 80 percent versus the previously guided range of 76 to 78 percent.”
Company outlook: “Pacira is reiterating its remaining full-year 2025 financial guidance as follows Non-GAAP R D expense of $90 million to $105 million Non-GAAP SG A expense of $290 million to $320 million and Stock-based compensation of $56 million to $61 million.”
Revenue — Raised (“increased”)
“2025 Financial Guidance Today the company is updating its full-year 2025 total revenue and non-GAAP gross margin guidance as follows Total revenue is narrowed to the range of $730 million to $750 million versus the previously guided range of $725 million to $765 million and Non-GAAP gross margin is increased to 78 to 80 percent versus the previously guided range of 76 to 78 percent.”
Company outlook — Reiterated (“reiterating”)
“Pacira is reiterating its remaining full-year 2025 financial guidance as follows Non-GAAP R D expense of $90 million to $105 million Non-GAAP SG A expense of $290 million to $320 million and Stock-based compensation of $56 million to $61 million.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Second Quarter 2025 Financial Highlights Total revenues of $181.1 million Net product sales of $142.9 million for EXPAREL, $31.3 million for ZILRETTA, and $5.6 million for iovera Net loss of $4.8 million, or $0.11 per share (basic and diluted) Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $54.3 million Non-GAAP net income of $36.0 million, or $0.79 per share (basic) and $0.74 per share (diluted) Repurchased 2.0 million shares of common stock at an average price of $25.59 per share, for a cost of $50.0 million See Non-GAAP Financial Information below.
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
New $300 Million Revolving Credit Facility.
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
In July, the company repaid and terminated its existing term loan A credit facility using a partial draw from a new $300 million, five-year Revolving Credit Facility.
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
This new credit facility bolsters the company s liquidity, financial flexibility, and ability to execute its capital allocation strategy as it advances its 5x30 growth strategy.
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
The new credit facility will benefit interest expense by 60 basis points per year beginning in 2026.
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
On August 1, 2025, the company s 0.750% convertible senior notes due 2025 matured and were repaid using $202.5 million of cash on hand.
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Strategy & priorities
htm EX-99.1 Document FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Second Quarter 2025 Financial Results -- Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth -- -- Conference call today at 4 30 p.
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Throughout the second quarter, we continued to make important progress advancing our 5x30 growth strategy to accelerate topline growth and fuel our transition into an innovative biopharmaceutical organization, said Frank D.
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
We continue to focus on driving broad market adoption for EXPAREL.
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Recent Business Highlights Meaningfully Advance 5x30 Growth Strategy Phase 2 Study of PCRX-201 in Osteoarthritis of the Knee Surpasses 50% Enrollment.
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
This new credit facility bolsters the company s liquidity, financial flexibility, and ability to execute its capital allocation strategy as it advances its 5x30 growth strategy.
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Risks & headwinds
This platform solves many of the challenges in the field of gene therapy that have prevented its utilization in treating common diseases, such as osteoarthritis.
SEC original ↗Pacira BioSciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Legal Proceedings 53 Item 1A.
SEC original ↗Pacira BioSciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026
Pacira is subject to risks common to companies in similar industries and stages, including, but not limited to, competition from larger companies and potential generic entrants, reliance on revenue from two commercialized products, reliance on a limited number of wholesalers, reliance on a limited number of manufacturing sites, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, tariffs, protection of proprietary technology, compliance with government regulations and risks related to cybersecurity.
SEC original ↗Pacira BioSciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026
The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved.
SEC original ↗Pacira BioSciences, Inc. — 10-Q Quarterly report10-QAug 4, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
30 documents- Q3 2026
- 8-KPCRX
- Q2 2026
- 8-KPCRX
- 10-QPCRX
- Q1 2026
- 8-KPCRX
Jun 30, 2026
- 8-KPCRX
Jun 11, 2026
- 8-KPCRX
Apr 30, 2026
- 10-QPCRX
Apr 30, 2026
- Q4 2025
- 8-KPCRX
Feb 26, 2026
- 10-KPCRX
Feb 26, 2026
- 8-KPCRX
Jan 28, 2026
- 8-KPCRX
- Q3 2025
- 8-KPCRX
- 10-QPCRX
- Q2 2025
- 8-KPCRX
- 10-QPCRX
- 8-KPCRX
Jul 10, 2025
- 8-KPCRX
- Q1 2025
- 8-KPCRX
Jun 13, 2025
- 8-KPCRX
- 10-QPCRX
- 8-KPCRX
Apr 22, 2025
- 8-KPCRX
- Q4 2024
- 8-KPCRX
Mar 14, 2025
- 8-KPCRX
Feb 27, 2025
- 10-KPCRX
Feb 27, 2025
- 8-KPCRX
Jan 30, 2025
- 8-KPCRX
Jan 21, 2025
- 8-KPCRX
Jan 10, 2025
- Q3 2024
- 8-KPCRX
- 10-QPCRX
Earnings releases
13 documentsPresentations
0 documentsNo presentations for Pacira BioSciences, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Pacira BioSciences, Inc. are held in this edition of the library.
Mentioned by
1 companyOther tracked companies whose held documents mention Pacira BioSciences, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
“t markets within its global infrastructure. 1 “The pending acquisition of Pacira BioSciences is an important step in advancing our strategy to build our innovative medicines… …applicable. Viatris Free cash flow refers to U.S. ”
See also the earnings calendar for every tracked company’s next earnings date.